Taj
Quality Medicines Diseases Newsroom Feed back Contact us
Search

 
 
 

Taj Product Development Book
         Taj Pharmaceuticals Pipelines
Product Development
 
Definitions:

This document outlines the Taj pharmaceuticals product development portfolio as of

31-DEC-04


including new molecular entities and major line extensions. The portfolio will change with time as compounds enter from research, progress through to the next phase of development or enter the market place. The high risk nature of the drug development process also means that it is not unusual for some projects to be terminated if they do not meet the criteria for progression and this will be particularly true in the early stages.

 
Definitions:

Phase 0:  Successful lead optimisation compounds will move into what we call phase zero. These are compounds where specific studies for registration have been initiated and preparation is underway for entry into humans.

Phase 1: Phase 1 is defined as the stage of development where safety studies are initiated and the drug first enter humans.

Phase 2:  This phase of development represents the first trials of study efficacy of the compound in humans.

Phase 3: This represents the larger clinical trial usually involving a comparision against a standard comparator compound in preparation for the registration of the compound and approval by regulatory authorities.
 
Taj World

Humen Structure

 
  Company   Products   Diseases   Health   Media   R & D   Sustainability  
  Figure & Reports   Investors   Countries   E-mail us      Divisions   Contact us   Home  

         Copyright 2005 TAJ Pharmaceuticals Limited ,434 LAXMI PLAZA (LAXMI INDUSTRIAL ESTATE) NEW LINK ROAD Andheri (W) MUMBAI-53. INDIA

Site Requirements : Internet Explorer 5.0+ or Netscape 5.0+, Flash Player 5.0 & Real Player 8 Basic
To get in touch with us, call on 91-22-2637 4592, 91--22-2637 4593 or fax us at 91-22-2634 1274 

| Privacy Policy | Terms & Conditions | Sitemap |